BVC:LSE-BATM Advanced Communications Ltd (GBX)

COMMON STOCK | Medical Instruments & Supplies | LSE

Last Closing Price

GBX 86.60

Change

-1.40 (-1.59)%

Market Cap

GBX 0.39B

Volume

0.25M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CTEC:LSE ConvaTec Group Plc

+0.40 (+0.18%)

GBX4.46B 55.65 12.40
AMS:LSE Advanced Medical Solutions Gro..

+1.00 (+0.37%)

GBX0.58B 68.46 31.14
TSTL:LSE Tristel plc

+5.00 (+0.90%)

GBX0.26B 49.55 27.18
ODX:LSE Omega Diagnostics Group PLC

N/A

GBX0.13B 16.43 106.33

ETFs Containing BVC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.88% 20% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.88% 20% F 14% F
Trailing 12 Months  
Capital Gain -13.23% 20% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.23% 20% F 7% F
Trailing 5 Years  
Capital Gain 441.25% 100% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 441.25% 100% A+ 95% A
Average Annual (5 Year Horizon)  
Capital Gain 66.18% 80% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.18% 80% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 57.39% 40% F 22% F
Risk Adjusted Return 115.33% 80% B- 94% A
Market Capitalization 0.39B 60% D- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 55.00 60% D- 18% F
Price/Book Ratio 4.71 60% D- 21% F
Price / Cash Flow Ratio 21.00 80% B- 24% F
EV/EBITDA 19.62 80% B- 35% F
Management Effectiveness  
Return on Equity 10.29% 80% B- 75% C
Return on Invested Capital 10.81% 60% D- 77% C+
Return on Assets 4.56% 80% B- 76% C
Debt to Equity Ratio 0.55% 100% A+ 90% A-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.17 100% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.